Skip to main content

Vik Chopra

Stock Analyst at Wells Fargo

Total Price Targets
9
Stocks Covered
9
Sectors
Healthcare, Industrials, Technology
Most Recent
Feb 14, 2025

Stocks Covered by Vik Chopra

SymbolCompanyLatest TargetCurrent PriceUpside# TargetsLast Updated
ADIAnalog Devices, Inc.$255.00$398.13-36.0%1Feb 14, 2025
ATECAlphatec Holdings, Inc.$19.00$10.43+82.2%1Oct 15, 2024
NVSTEnvista Holdings Corp$20.00$26.26-23.8%1Oct 8, 2024
NPCENeuroPace, Inc.$15.00$17.04-12.0%1Aug 14, 2024
GMEDGlobus Medical, Inc.$78.00$91.62-14.9%1Aug 7, 2024
IARTIntegra LifeSciences Holdings Corporation$25.00$10.85+130.4%1May 6, 2024
SOLVSolventum Corporation$69.00$66.97+3.0%1Apr 8, 2024
MASIMasimo Corporation$160.00$178.56-10.4%1Mar 25, 2024
ENOVEnovis Corporation$67.00$23.61+183.8%1May 12, 2023

Recent Activity

  • Feb 14, 2025— Set$255.00price target onADI(Analog Devices, Inc.)
  • Oct 15, 2024— Set$19.00price target onATEC(Alphatec Holdings, Inc.)
  • Oct 8, 2024— Set$20.00price target onNVST(Envista Holdings Corp)
  • Aug 14, 2024— Set$15.00price target onNPCE(NeuroPace, Inc.)
  • Aug 7, 2024— Set$78.00price target onGMED(Globus Medical, Inc.)
  • May 6, 2024— Set$25.00price target onIART(Integra LifeSciences Holdings Corporation)
  • Apr 8, 2024— Set$69.00price target onSOLV(Solventum Corporation)
  • Mar 25, 2024— Set$160.00price target onMASI(Masimo Corporation)
  • May 12, 2023— Set$67.00price target onENOV(Enovis Corporation)

Frequently Asked Questions

Who is Vik Chopra?

Vik Chopra is a stock analyst at Wells Fargo covering 9 stocks primarily in Healthcare, Industrials, Technology. They have issued 9 price targets since May 12, 2023.

What stocks does Vik Chopra cover?

Vik Chopra currently covers 9 stocks, including ADI, ATEC, NVST, NPCE, GMED.

What is Vik Chopra's latest price target?

Vik Chopra's most recent price target was $255.00 on ADI (Analog Devices, Inc.), set on Feb 14, 2025.

What is Vik Chopra's highest price target?

Vik Chopra's highest issued price target is $255.00 on ADI, set on Feb 14, 2025.

Coverage based on publicly published price targets. Not investment advice.